Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF

Recruiting now

Conditions studied: Hepatitis B, Chronic, Acute-On-Chronic Liver Failure

In brief

This study is to investigate investigate the safety and efficacy of Double plasma molecular adsorption system with sequential low-dose plasma exchange in treating hepatitis B virus-related acute-on-chronic liver failure.

Key facts

Study ID

NCT04597164

Run by

Third Affiliated Hospital, Sun Yat-Sen University

People needed

200

Starts

2020-12-22

Expected to finish

2024-12-31

Last updated by the study team

2024-11-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA > 0.5 year);
• Age from 18 to 65 years old;
• Clinical diagnosis of liver failure (serum total bilirubin level > 10 times upper limit of normal; prothrombin time activity < 40% and ≥20%, or prothrombin time international ratio ≤ 2.6 and > 1.5);
• Platelets > 50*10 E9/L.

You may not qualify if…

• Other active liver diseases;
• Hepatocellular carcinoma or other malignancy;
• Pregnancy or lactation;
• Human immunodeficiency virus infection or congenital immune deficiency diseases;
• Severe diabetes, autoimmune diseases; unstable infarction due to cardio-cerebrovascular events;
• Other important organ dysfunctions or transplantation;
• Severe complications including severe infection, gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome;
• Patients can not follow-up;
• Investigator considering inappropriate.

Where it is running

• Third Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.